{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:34:10Z","timestamp":1789205650532,"version":"build-2803163510"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T00:00:00Z","timestamp":1650758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs, LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with high-risk, newly diagnosed multiple myeloma (HR-NDMM) who are ineligible for autologous stem cell transplant (ASCT) have limited first-line treatment options. Recent meta-analyses evaluating the impact of incorporating daratumumab in the backbone regimen on progression-free survival (PFS) have found mixed results in these patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>A pooled analysis of patient-level data for ASCT-ineligible patients with HR-NDMM [ie, del(17p), t(4;14), t(14;16)] from the MAIA and ALCYONE trials; stratified by study identifier and adjusting for cytogenetic abnormality subtype, baseline performance status, International Staging System stage, myeloma type, and renal impairment; was conducted. Impact of daratumumab on PFS and rates of complete response or better (\u2265CR), minimal residual disease (MRD)-negative CR, very good partial response or better (\u2265VGPR), and overall response (ORR) was compared to control.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 101 patients in the daratumumab and 89 patients in the control cohort, median follow-up was 43.7 months. Daratumumab reduced the risk of progression or death by 41% (adjusted hazard ratio for PFS [95% confidence interval (CI)] = 0.59 [0.41-0.85]) versus control. At 36 months, the estimated proportion of patients who did not progress and were still alive was 41.3% in the daratumumab and 19.9% in the control cohort. Rates of \u2265CR (41.6% vs. 22.5%), MRD-negative CR (24.8% vs. 5.6%), \u2265VGPR (75.2% vs. 46.1%), and ORR (92.1% vs. 74.2%) were higher for daratumumab versus control.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These findings demonstrate that incorporation of daratumumab in frontline treatment regimens reduced the risk of progression or death and improved response rates among ASCT-ineligible HR-NDMM patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac067","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T04:15:51Z","timestamp":1648181751000},"page":"e589-e596","source":"Crossref","is-referenced-by-count":29,"title":["Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma"],"prefix":"10.1093","volume":"27","author":[{"given":"Andrzej J","family":"Jakubowiak","sequence":"first","affiliation":[{"name":"University of Chicago Medical Center , Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Medhekar","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC , Horsham, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Pei","sequence":"additional","affiliation":[{"name":"Janssen Research & Development , Raritan, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchita","family":"Kaila","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC , Horsham, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"He","sequence":"additional","affiliation":[{"name":"Janssen Global Services, LLC , Raritan, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Lafeuille","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelore","family":"Cortoos","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC , Horsham, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Londhe","sequence":"additional","affiliation":[{"name":"Janssen Research & Development , Raritan, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Mavros","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC , Horsham, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S","family":"Lin","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC , Horsham, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z","family":"Usmani","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute, Atrium Health , Charlotte, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,24]]},"reference":[{"key":"2022070520465832900_CIT0001","doi-asserted-by":"crossref","first-page":"f3863","DOI":"10.1136\/bmj.f3863","article-title":"Multiple myeloma.","volume":"346","author":"Smith","year":"2013","journal-title":"BMJ"},{"issue":"3","key":"2022070520465832900_CIT0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger).","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"2022070520465832900_CIT0003","author":"National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results Program (SEER).","year":"2020"},{"issue":"5","key":"2022070520465832900_CIT0004","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2022070520465832900_CIT0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"issue":"8","key":"2022070520465832900_CIT0006","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome.","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2022070520465832900_CIT0007","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and \u221217p13 in myeloma patients treated with high-dose therapy.","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"issue":"26","key":"2022070520465832900_CIT0008","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group.","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022070520465832900_CIT0009","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/EDBK_200879","article-title":"Risk stratification and targets in multiple myeloma: from genomics to the bedside.","volume":"38","author":"Perrot","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"2022070520465832900_CIT0010","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41375-018-0098-9","article-title":"Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents.","volume":"32","author":"Avet-Loiseau","year":"2018","journal-title":"Leukemia"},{"key":"2022070520465832900_CIT0011","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/EDBK_175171","article-title":"Myeloma in elderly patients: when less is more and more is more.","volume":"37","author":"Rosko","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"2022070520465832900_CIT0012","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma.","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"22","key":"2022070520465832900_CIT0013","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma.","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"2022070520465832900_CIT0014","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma.","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"10218","key":"2022070520465832900_CIT0015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"2022070520465832900_CIT0016","doi-asserted-by":"crossref","first-page":"103211","DOI":"10.1016\/j.critrevonc.2020.103211","article-title":"Daratumumab-based induction therapy for multiple myeloma: a systematic review and meta-analysis.","volume":"159","author":"Chong","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10192","key":"2022070520465832900_CIT0017","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"2022070520465832900_CIT0018","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/jha2.47","article-title":"Use of daratumumab in high risk multiplemyeloma: a meta-analysis.","volume":"1","author":"Premkumar","year":"2020","journal-title":"eJHaem"},{"issue":"Supplement_1","key":"2022070520465832900_CIT0019","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2019-123426","article-title":"Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant: updated analysis of Maia.","volume":"134","author":"Bahlis","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2022070520465832900_CIT0020","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk &#x2028;cytogenetic factors: a systematic review and meta-analysis.","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncol"},{"key":"2022070520465832900_CIT0021","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-134847","article-title":"Updated analysis of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM): the phase 3 Maia Study.","author":"Kumar","year":"2020"},{"issue":"3","key":"2022070520465832900_CIT0022","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","article-title":"Using effect size-or why the P value is not enough.","volume":"4","author":"Sullivan","year":"2012","journal-title":"J Grad Med Educ"},{"issue":"6","key":"2022070520465832900_CIT0023","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research.","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat - Simul Comput"},{"issue":"8","key":"2022070520465832900_CIT0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/03000605211038135","article-title":"Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis.","volume":"49","author":"Wang","year":"2021","journal-title":"J Int Med Res"},{"issue":"11","key":"2022070520465832900_CIT0025","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2022070520465832900_CIT0026","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/leu.2013.220","article-title":"Association of response endpoints with survival outcomes in multiple myeloma.","volume":"28","author":"Lonial","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"2022070520465832900_CIT0027","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","article-title":"Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma.","volume":"92","author":"van de Velde","year":"2007","journal-title":"Haematologica"},{"issue":"22","key":"2022070520465832900_CIT0028","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood.2020007522","article-title":"Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.","volume":"136","author":"Jasielec","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2022070520465832900_CIT0029","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2022070520465832900_CIT0030","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/asheducation-2016.1.485","article-title":"Myeloma: management of the newly diagnosed high-risk patient.","volume":"2016","author":"Dispenzieri","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2022070520465832900_CIT0031","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/7\/e589\/44418230\/oyac067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/7\/e589\/44418230\/oyac067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T20:47:45Z","timestamp":1657054065000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/7\/e589\/6573343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,24]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4,24]]},"published-print":{"date-parts":[[2022,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac067","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,4,24]]}}}